--- title: "U.S. stock market midday update: Scribe Therapeutics up 20.75%, OrbiMed increases holdings by 1 million shares boosting confidence" type: "News" locale: "en" url: "https://longbridge.com/en/news/294397015.md" description: "Scribe Therapeutics rose 20.75%; Alibaba's Amgen fell 29.79%, with a transaction volume of USD 1.122 billion; AbbVie fell 1.87%, with a transaction volume of USD 661 million; Madrigal Pharmaceuticals fell 10.65%, with a transaction volume of USD 499 million; Amgen fell 0.71%, with a market value of USD 207.7 billion" datetime: "2026-07-30T17:08:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294397015.md) - [en](https://longbridge.com/en/news/294397015.md) - [zh-HK](https://longbridge.com/zh-HK/news/294397015.md) --- # U.S. stock market midday update: Scribe Therapeutics up 20.75%, OrbiMed increases holdings by 1 million shares boosting confidence **U.S. Stock Market Midday Update** Scribe Therapeutics rose 20.75%. Based on recent key news: 1. On July 29, OrbiMed Advisors increased its indirect common stock holdings in Scribe Therapeutics to 1,348,825 shares and acquired 1 million shares at a price of $15 per share. This news drove the stock price up, indicating increased market confidence in the company. Source: EDGAR system disclosure 2. On July 29, OrbiMed Advisors, as a board member of Scribe Therapeutics, continued to support the innovative drug developer and played a significant role in biotechnology IPOs. This further heightened investor interest in Scribe Therapeutics, leading to a rise in stock price. Source: SEC filings 3. No other significant news recently. The biotechnology industry has shown strong performance lately, with noticeable capital inflows. **Top Stocks by Trading Volume in the Industry** Alnylam Pharmaceuticals fell 29.79%. Based on recent key news: 1. On July 30, Alnylam Pharmaceuticals lowered its 2026 net product revenue guidance to $4.7 billion to $5.1 billion, down from the previous expectation of $4.9 billion to $5.3 billion, resulting in a significant drop in stock price. The company's second-quarter sales were $1.29 billion, below analysts' expectations of $1.32 billion, with adjusted earnings per share of $1.84, exceeding the expected $1.55. Source: Reuters 2. On July 30, the company stated that the change in TTR net product revenue guidance reflects the normalization of demand for AMVUTTRA in the second line in the U.S. market, leading to a 21.15% drop in stock price during pre-market trading. Source: RTT News 3. On July 30, market analysts did not include Alnylam Pharmaceuticals in their recommended buy list, despite its rating being moderate buy, which undermined investor confidence. Source: MarketBeat The biopharmaceutical industry faces risks of revenue expectation adjustments. AbbVie fell 1.87%. Based on recent key news: 1. On July 29, AbbVie's Humira revenue continued to decline due to intensified competition from biosimilars, but strong performances from Skyrizi and Rinvoq drove immunology revenue growth of 16.4%. This indicates that AbbVie is successfully rebuilding its growth engine, although Humira faces pressure, overall performance remains positive. 2. On July 28, AbbVie faced prescription pressure from major pharmacy benefit managers, threatening the revenue base in the immunology sector. Additionally, the high-cost R&D integration risks from recent acquisitions and potential setbacks in clinical trials have raised market concerns On July 30, JP Morgan recommended AbbVie as one of the top picks in the biopharmaceutical industry. Despite facing risks from patent cliffs and drug pricing reforms, analysts believe these risks are reflected in the valuations, limiting potential downside. The biopharmaceutical industry faces risks from patent cliffs. Madrigal Pharmaceuticals fell 10.65%. Based on recent key news: 1. On July 30, Madrigal Pharmaceuticals reported a net income of -$57.939 million for the second quarter, with operating expenses reaching $420.56 million, leading to a decline in stock price. The company's poor financial performance affected investor confidence, putting pressure on the stock price. 2. On July 30, Madrigal Pharmaceuticals launched the "MASH Across America" disease education campaign, increasing commercial investments, including growth in the endocrine field and direct-to-consumer marketing. Despite positive market activities, it failed to offset the negative impact of financial pressures on the stock price. 3. On July 30, Madrigal Pharmaceuticals' net sales increased by 71% year-over-year to $364.3 million; however, due to increased commercial and R&D investments, operating expenses and net losses also rose. Despite significant sales growth, high operating costs continue to pressure the stock price. Industry investments have increased, and financial pressures are significant. **Stocks ranked at the top of the industry by market capitalization** Amgen fell 0.71%, with increased trading volume. Based on recent key news: 1. On July 29, Amgen's Repatha received support from the European Medicines Agency, expanding its indications for reducing cardiovascular disease risk. This news boosted market confidence in the drug but failed to fully offset other negative factors. 2. On July 29, analyst Emily Field maintained a hold rating on Amgen and set a target price of $360. Despite the unchanged rating, concerns about future growth remain in the market. 3. On July 29, Amgen discovered a decrease in bone density among participants in clinical trials, triggering safety alerts and putting pressure on the stock price. Analysts believe this finding poses a significant risk to the company's long-term growth. There are concerns in the market about the future growth of the biotechnology industry ### Related Stocks - [SCTX.US](https://longbridge.com/en/quote/SCTX.US.md) - [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [MDGL.US](https://longbridge.com/en/quote/MDGL.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [OrbiMed Advisors Discloses Investment in Scribe Therapeutics with 7.2% Stake](https://longbridge.com/en/news/294271636.md) - [Scribe Therapeutics CFO David Parrot reports $ 39,990 common stock acquisition](https://longbridge.com/en/news/293991409.md) - [Principal Financial Group Inc. Sells 6,022 Shares of Madrigal Pharmaceuticals, Inc. $MDGL](https://longbridge.com/en/news/294578126.md) - [Dimensional Fund Advisors LP Lowers Holdings in Corcept Therapeutics Incorporated $CORT](https://longbridge.com/en/news/294598913.md) - [Behzad Aghazadeh Holds Board Seat at Scribe Therapeutics with 16.37% Stake](https://longbridge.com/en/news/294437888.md)